Caris Discovery

Let Caris help you unlock truly novel and otherwise inaccessible targets for your discovery pipeline.

Biopharma
Discovery
Clinical Development
Commercialization
Contact

Leverage Unmatched Resources to Identify Novel, Clinically Relevant Targets

Biopharma Discovery with Caris uses leverages real-world data

REAL-WORLD PATIENT POPULATIONS ACROSS TUMOR TYPES

525,000 AND GROWING

Highly Differentiated, Orthogonal Multi-Omics Method for Target Discovery

Adaptive dynamic artificial polyligand targeting (ADAPT)

Unbiased target ID platform that uses a broad library of aptamers to profile biological samples at a systems-wide scale

Repository of over 9M+ FFPE slides across oncology

Unparalleled data

The breadth of Caris’ molecular and clinical database provides an unmatched ability to identify actionable targets

WES and WTS: full coverage DNA & RNA molecular information paired to clinical outcomes data

Caris Biopharma Discovery uses multiple technologies for target discovery

Wet Lab Validation and Characterization Workflow Includes a Robust Suite of Assays Tailored to Modality

MOLECULAR MATCHED CLINICAL SAMPLES

  • Protein expression

  • Cell surface expression

  • Epitope mapping

  • Antibody specificity/ sensitivity

59,000 SQ FT DISCOVERY LAB

  • 23 Pathologists
  • 60+ Cell Lines
  • 38 Ventana & Dako Instruments
  • 35+ Validated Antibodies

Differentiation and Aggregate Strength of the Caris Platform Unlocks Otherwise Inaccessible Target Discovery Opportunities

  • 23,000+

    encoding DNA genes

  • 61,000

    RNA transcripts

  • 525K+

    molecular tumor profiles

  • 417K+

    profiles with matched clinical data

  • 9M+

    slides

  • 1 Trillion

    daily "reads" capacity

  • ADAPT

    aptamer biotargeting system

  • Proximity Labeling

    multi-specific interactions

  • Cell Surfaceome

    >3,000 proteins identified

  • Sensitivity & Specificity

    antibodies IHC & flow cytometry

  • Target Expression

    normal vs. cancer tissue

  • 80+

    POA leading cancer institutions

  • 56

    countries with presence

  • 300+

    specialized oncology salesforce

  • 300K+

    sq. ft. of lab space

  • 4

    precision medicine labs

unparalleled data

innovation lab

broad footprint

Note: Data current as of July 7, 2023

unparalleled data

  • 23,000+

    encoding DNA genes

  • 61,000

    RNA transcripts

  • 525K+

    molecular tumor profiles

  • 417K+

    profiles with matched clinical data

  • 9M+

    slides

  • 1 Trillion

    daily "reads" capacity

innovation lab

  • ADAPT

    aptamer biotargeting system

  • Proximity Labeling

    multi-spcific interactions

  • Cell Surfaceome

    >3,000 proteins identified

  • Sensitivity & Specificity

    antibodies IHC & flow cytometry

  • Target Expression

    normal vs. cancer tissue

broad footprint

  • 80+

    POA leading cancer institutions

  • 56

    countries with presence

  • 300+

    specialized oncology salesforce

  • 300K+

    sq. ft. of lab space

  • 4

    precision medicine labs

Note: Data current as of July 7, 2023

State of the Art Equipment and Facilities for Target ID and Drug Development

Footprint of 45 NovaSeqs

nova sequencing machine
  • Leading high throughput oncology profiling lab for NovaSeqs in U.S.
  • Improvements in throughput efficiencies
  • Enhanced depth of coverage

4 Precision Medicine Laboratories (Phoenix and Dallas)
Totaling 300K+ Sq. Ft.

Clinical Tissue Lab

Clinical Tissue Lab
(Cotton Center,
Phoenix, AZ)

Biopharma Discovery Drug Target Lab

Drug Target Discovery Lab
(Papago,
Phoenix, AZ)

Clinical Blood Lab

Clinical Blood Lab
(Cotton Center,
Phoenix, AZ)

Clinical Tissue and Blood Lab

Coming Soon -
Clinical Tissue & Blood Lab
(Irving, TX)

AI Technology Enabled Platform for Target Discovery Agnostic to Treatment Modality

Multiple filters can be applied based on specific partner requirements

HUMAN
GENOME

Starting from human genome

DISEASE PREVALENCE / SPECIFICITY & RWE

Filtered using epidemiology, Real World Evidence data, and/or other partner specific requirements

PROTEIN TARGET VALIDATION

Further narrowed down candidates by using various wet lab validation techniques

100s of novel target candidates to validate and partner externally

HUMAN
GENOME

Starting from human genome

DISEASE PREVALENCE/ SPECIFICITY & RWE

Filtered using epidemiology, Real World Evidence data, and/or other partner specific requirements

PROTEIN TARGET VALIDATION

Further narrowed down candidates by using various wet lab validation techniques

100s of novel target candidates to validate and partner externally

Modality-Agnostic Targets

Novel Cell Surface Targets

Druggable Genomic Alterations

Synthetic Lethality

Protein Degraders

Neo-antigens

Acquired Resistance

Contact Us

"*" indicates required fields

Name*
Preferred contact method*
Best time to contact
: